Validation of linear cerebral atrophy markers in multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Progressive cerebral atrophy in multiple sclerosis. A serial MRI study.
Recent studies of the spinal cord and cerebellum have highlighted the importance of atrophy in the development of neurological impairment in multiple sclerosis. We have therefore developed a technique to quantify the volume of another area commonly involved pathologically in multiple sclerosis: the cerebral white matter. The technique we describe extracts the brain from the skull on four contig...
متن کاملAdrenocortical atrophy and diffuse cerebral sclerosis.
Forsyth, C. C., Forbes, M., and Cumings, J. N. (1971). Archives of Disease in Childhood, 46, 273. Adrenocortical atrophy and diffuse cerebral sclerosis. A boy, diagnosed as having Addison's disease due to idiopathic atrophy of the adrenal glands at the age of 7 years, developed the first evidence of what was originally thought to be 'Schilder's disease' at 8 years and 10 months. He died at 9 ye...
متن کاملRegional hippocampal atrophy in multiple sclerosis.
Gray matter brain structures, including deep nuclei and the cerebral cortex, are affected significantly and early in the course of multiple sclerosis and these changes may not be directly related to demyelinating white matter lesions. The hippocampus is an archicortical structure that is critical for memory functions and is especially sensitive to multiple insults including inflammation. We use...
متن کاملMultiple cerebral gliomas in multiple sclerosis.
A patient with multiple sclerosis and a multicentric anaplastic astrocytoma is described. The evidence suggests that the relationship is not coincidental and that the astrocytomas originate in multiple sclerosis plaques.
متن کاملThe Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
INTRODUCTION The objective of this pilot study was to compare cerebral gray matter (GM) atrophy over 1 year in patients starting dimethyl fumarate (DMF) for multiple sclerosis (MS) to that of patients on no disease-modifying treatment (noDMT). DMF is an established therapy for relapsing-remitting (RR) MS. METHODS We retrospectively analyzed 20 patients with RRMS at the start of DMF [age (mean...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Neuroscience
سال: 2008
ISSN: 0967-5868
DOI: 10.1016/j.jocn.2007.02.089